Antiplatelets

Question 1

What is the MoA of aspirin?

Answer 1

COX inhibitor

Aspirin irreversibly inhibits COX, reducing thromboxane A₂ production and platelet aggregation.

TXA2 usually gets released to go bind on another plt, cause change in conformation and plt degranulation

Question 2

What is the indication for Aspirin?

Answer 2

Primary/secondary prevention of MI and stroke

Aspirin is used for both primary and secondary prevention of myocardial infarction (MI) and stroke.

Question 3

What are the common side effects of Aspirin?

Answer 3

• GI bleeding
• Dyspepsia
• Increased bleeding risk
• Contraindicated in children (Reye syndrome)

Question 4

What is the MoA of Clopidogrel (Plavix)?

Answer 4

ADP receptor antagonist

Clopidogrel irreversibly blocks the ADP receptor, reducing platelet activation and aggregation.

ADP receptor binding activates another GP2b/3a on membrane which is resp for crosslinking of plts w/fibrinogen

Question 5

What is the primary use of Clopidogrel?

Answer 5

MI, stroke prevention, stent thrombosis

Clopidogrel is primarily used for prevention of myocardial infarction, stroke, and stent thrombosis.

Question 6

What are the common side effects of Clopidogrel?

Answer 6

• Bleeding risk
• Neutropenia
• Possible drug interactions

Question 7

What type of drug is Tirofiban (Aggrastat)?

Answer 7

GPIIb/IIIa antagonist.

Tirofiban inhibits the binding of fibrinogen to the GPIIb/IIIa receptor, preventing platelet aggregation.

Question 8

What is the primary use of Tirofiban?

Answer 8

Acute coronary syndromes, percutaneous coronary interventions

Tirofiban is used in the treatment of acute coronary syndromes and during percutaneous coronary interventions.

Question 9

What are the common side effects of Tirofiban?

Answer 9

• Bleeding
• Thrombocytopenia
• Hypotension

Question 10

What type of drug is Vorapaxar (Zontivity)?

Answer 10

PAR-1 receptor inhibitor

Vorapaxar blocks protease-activated receptor-1 by blocking its conformational change after cleavage, reducing thrombin-induced platelet activation.

Question 11

What is the primary use of Vorapaxar?

Answer 11

Secondary prevention in patients with prior MI or PAD

Vorapaxar is used for secondary prevention in patients who have had a previous myocardial infarction (MI) or peripheral artery disease (PAD).

Question 12

What are the common side effects of Vorapaxar?

Answer 12

Increased risk of bleeding, including intracranial hemorrhage

The bleeding risk associated with Vorapaxar is significant, particularly for intracranial hemorrhage.